Safe and Effective Delivery of Nucleic Acids Using Proteolipid Vehicles Formulated with Fusion-Associated Small Transmembrane Proteins

Brown, DJ; Wee, Ping; Bhandari, Prakash; Vega, Héctor; Grin, Liliya; Sosnowski, Deborah; Hejazi, Maryam; Ablack, Jailal; Clancy, Eileen K.; Pink, Desmond; Kumar, J.; Ares, Paola Solis; Lamb, Suellen; McMullen, Nichole; MacKenzie, Duncan S.; Beatty, Perrin H.; García, Henry David Mogollón; Parmar, Manoj; Gyoba, Jennifer; Scholz, Matthew; Duncan, Roy; Raturi, Arun; Lewis, John D.

doi:10.2139/ssrn.4241169

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rationales and mechanisms behind LNP internalization, endosomal escape and organ/cell-selective delivery have been widely investigated by multiple groups using either siRNA or mRNA as the delivered molecules [533]. In brief, apolipoprotein E(ApoE) or albumin-based receptor mediated endocytosis and non-specific micropinocytosis are two major mechanisms responsible for the update of mRNA/siRNA loaded LNPs [534].…”

Section: Mechanistic Studies and Additional Functional Modifications ...mentioning

confidence: 99%

The use of RNA-based treatments in the field of cancer immunotherapy

Chehelgerdi

2023

Mol Cancer

View full text Add to dashboard Cite

Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a clinical reality. These vaccines offer several advantages over traditional vaccine techniques, including their high potency, rapid development, low-cost manufacturing, and safe administration. However, until recently, concerns over the instability and inefficient distribution of mRNA in vivo have limited their utility. Fortunately, recent technological advancements have mostly resolved these concerns, resulting in the development of numerous mRNA vaccination platforms for infectious diseases and various types of cancer. These platforms have shown promising outcomes in both animal models and humans. This study highlights the potential of mRNA vaccines as a promising alternative approach to conventional vaccine techniques and cancer treatment. This review article aims to provide a thorough and detailed examination of mRNA vaccines, including their mechanisms of action and potential applications in cancer immunotherapy. Additionally, the article will analyze the current state of mRNA vaccine technology and highlight future directions for the development and implementation of this promising vaccine platform as a mainstream therapeutic option. The review will also discuss potential challenges and limitations of mRNA vaccines, such as their stability and in vivo distribution, and suggest ways to overcome these issues. By providing a comprehensive overview and critical analysis of mRNA vaccines, this review aims to contribute to the advancement of this innovative approach to cancer treatment.

show abstract

Section: Mechanistic Studies and Additional Functional Modifications ...mentioning

confidence: 99%

The use of RNA-based treatments in the field of cancer immunotherapy

Chehelgerdi

2023

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…However, as researchers uncover more cancer cell signaling complexities, this objective seems unlikely to be effective. Despite this, precision medicine is a growing field with the discovery of novel targets and treatments at a rapid rate [ 21 , 24 , 25 , 26 , 27 ]. This review article discusses the targeted therapy approaches of one of the most promising yet complex anti-cancer drug targets, tumor protein p53.…”

Section: Introductionmentioning

confidence: 99%

Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53

Brown

Beatty²,

Lewis

2022

Cancers

View full text Add to dashboard Cite

While chemotherapy is a key treatment strategy for many solid tumors, it is rarely curative, and most tumor cells eventually become resistant. Because of this, there is an unmet need to develop systemic treatments that capitalize on the unique mutational landscape of each patient’s tumor. The most frequently mutated protein in cancer, p53, has a role in nearly all cancer subtypes and tumorigenesis stages and therefore is one of the most promising molecular targets for cancer treatment. Unfortunately, drugs targeting p53 have seen little clinical success despite promising preclinical data. Most of these drug compounds target specific aspects of p53 inactivation, such as through inhibiting negative regulation by the mouse double minute (MDM) family of proteins. These treatment strategies fail to address cancer cells’ adaptation mechanisms and ignore the impact that p53 loss has on the entire p53 network. However, recent gene therapy successes show that targeting the p53 network and cellular dysfunction caused by p53 inactivation is now possible and may soon translate into successful clinical responses. In this review, we discuss p53 signaling complexities in cancer that have hindered the development and use of p53-targeted drugs. We also describe several current therapeutics reporting promising preclinical and clinical results.

show abstract

Safe and Effective Delivery of Nucleic Acids Using Proteolipid Vehicles Formulated with Fusion-Associated Small Transmembrane Proteins

Cited by 2 publications

References 0 publications

The use of RNA-based treatments in the field of cancer immunotherapy

The use of RNA-based treatments in the field of cancer immunotherapy

Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53

Contact Info

Product

Resources

About